Thomas Schnitzer
Neuromusculoskeletal Medicine, Sports Medicine · Chicago, ILNPI 1588649461
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $271,213 of the $337,461 with a category attached, or 80.4%. 20 manufacturers reported payments, led by Pfizer at 30.4% of the total. Reporting peaked in 2019 at $106,684 and has fallen 85.0% since, to $16,034 in 2025.
Across 262 payments — averaging $1288.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$103K
- Eli Lilly$44K
- Lilly USA, LLC$34K
- Merck$28K
- IBSA Institut Biochimique SA$24K
- Astrazeneca UK Limited$22K
- plus $82K from 14 others
Across 393 payments — averaging $24,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6.2M
- Regeneron$1.6M
- Amgen$529K
- Vertex$353K
- Pfizer$327K
- GSK$256K
- plus $496K from 8 others
What the payments were for
- Consulting fees$271,21380%
- Speaking & faculty fees$19,7056%
- Travel & lodging$43,20913%
- Food & beverage$3,3341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $102,642 |
| Eli Lilly | 91 | $44,139 |
| Lilly USA, LLC | 42 | $34,466 |
| Merck | 38 | $28,382 |
| IBSA Institut Biochimique SA | 8 | $23,806 |
| Astrazeneca UK Limited | 8 | $21,719 |
| GSK | 10 | $20,124 |
| Noven Therapeutics, LLC | 4 | $9,117 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $7,909 |
| Alkermes, Inc. | 9 | $7,438 |
| Regeneron | 6 | $6,570 |
| Orion Corporation | 3 | $5,525 |
| Vertex | 3 | $5,250 |
| Collegium Pharmaceutical, Inc. | 1 | $4,713 |
| Novo Nordisk | 2 | $4,000 |
| Acadia Pharmaceuticals Inc | 3 | $3,710 |
| GRT US Holding, Inc. | 1 | $3,600 |
| Biotissue Holdings Inc. | 2 | $2,550 |
| Noven Pharmaceuticals, Inc. | 1 | $1,200 |
| AstraZeneca | 1 | $600 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromusculoskeletal medicine, sports medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.